"Mustard Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Strong alkylating and immunosuppressive agents whose biological activity is based on the presence of bis(2-chloroethyl)- groups. Although otherwise structurally diverse, the compounds have in common the capacity to contribute alkyl groups to DNA. They are generally highly toxic but include among their number many widely used and effective antineoplastic agents.
| Descriptor ID |
D009150
|
| MeSH Number(s) |
D02.455.526.728
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mustard Compounds".
Below are MeSH descriptors whose meaning is more specific than "Mustard Compounds".
This graph shows the total number of publications written about "Mustard Compounds" by people in this website by year, and whether "Mustard Compounds" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Mustard Compounds" by people in Profiles.
-
Inhibition of HIF-1a by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2015 Feb 10; 6(4):2250-62.
-
Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. 2013 Jun 01; 73(11):3235-47.
-
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol. 2010 Jul; 5(7):940-9.
-
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther. 2010 Jul; 9(7):2057-67.
-
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr; 8(4):947-58.
-
Phase II trail of PCNU in refractory advanced breast cancer. Am J Clin Oncol. 1982 Jun; 5(3):249-51.